Assistant Clinical Professor, Division of Hematology/Oncology, Medicine
School of Medicine

lymphoma, Bcl2 family, apoptosis

@DrLizBrem

LinkedIn

ASH Trainee Research Award 05/2012
ASH Abstract Achievement Award 12/2013
AACR/ASCO Methods in Clinical Cancer Research Workshop (Vail, CO) 07/2015
UC Irvine American Cancer Society Seed Grant Award 09/2016
Society of Hematologic Oncology (SoHo) Travel Grant 07/2017
National Institutes of Health (NIH) Clinical Loan Repayment Program 07/2017-9/2019
Top 20 Physician for Patient Satisfaction at UC Irvine 03/2018
LRF Lymphoma Clinical Research Mentoring Program 04/2018
SWOG Young Investigator Training Course, Hope Foundation 09/2018
Society of Hematologic Oncology (SoHo) Travel Grant 07/2019
Teacher of the Year, UCI Hematology/Oncology Fellowship 06/2021

Brem EA and O’Brien SM. Front Line Management of CLL in 2021. JCO Oncology Practice. ePub 21 July 2021.

Morrissette K, Bridwell R, Lentz S, Brem E, Gutierrez KO, Singh M, Koyfman A, Long B. Hemophagocytic Lymphohistiocytosis in the Emergency Department: Recognizing and Evaluating a Hidden Threat. J Emerg Med. 2021 Jun;60(6):743-751

Long B, Targonsky E, Brém E. Just the facts: febrile neutropenia in the emergency department setting. CJEM. 2021 Jul;23(4):445-449.

Lehrich BM, Goshtasbi K, Abiri A, Yasaka TM, Papagiannopoulos P, Tajudeen BA, Brem EA, Kuan EC. Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2021 Mar;62(3):727-730.

Long B, Brém E, Koyfman A. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. West J Emerg Med. 2020 Apr 13;21(3):566-580.

Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 Feb 7;133(6):566-575.

Khan Y, Brem EA. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly. Curr Hematol Malig Rep. 2019 Aug;14(4):228-238.

Robertson JJ, Brem E, and Koyfman A. The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management. J Emerg Med. E pub 10 April 2017.

Haverlok B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023;7(20):6339-6350.

Brem E, Koyfman A, Foran M. Review of Recently Approved Alternatives to Anticoagulation with Warfarin for Emergency Clinicians. J Emerg Med. 2013;45(1):143-9.

Koyfman A, Brem E, and Chiang V. Thrombotic Thrombocytopenic Purpura. Pediatric Emergency Care. 2011;27:1085-1091.

Brem E and Davids M. Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leukemia and Lymphoma. 2014;55(12):2675-2677.

Brem EA and Letai AG. BOK: Oddball of the BCL-2 Family. Trends in Cell Biology. 2016;26(6)389-90.

Brem EA and Sehn LH. Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities. Seminars in Hematology. 2023;60(5):285-290

Lee BJ, Cao Y, Vittayawacharin P, Leima G, Rezk S, Reid J, Brem EA, Ciurea SO, Kongtim P. Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis. Eur J Haematol. Accepted 14 June 2023.

Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA et al. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. ePub 27 April 2023.

Bitner BF, Htun NN, Wang BY, Brem EA, Kuan EC. Sinonasal lymphoma: A primer for otolaryngologists. Laryngoscope Investig Otolaryngol. 2022;7(6):1712-1724.

Kumar P, Brazel D, Benjamin DJ, Brem E. Eponyms in Malignant Hematology Cancer Treatment and Research Communications. 2022;32:100594.

Kumar P, Brazel D, Benjamin DJ, Brem E. Eponyms in Medical Oncology. Cancer Treatment and Research Communications. 2022;31:100516.

Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma and Leukemia. 2022;22(10)e947-e957.

Chilakamarri N, Olmedo K, Brem EA. The Current and Future of Marginal Zone Lymphoma Therapies. TouchREVIEWS in Oncology & Haematology. ePub 11 April 2022.

Brem EA and O’Brien SM. Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The Case for BTKi. Blood Advances. 2022;6(4):1361-1364.

Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alidadeh AA, Olin R, Henry NL, Dilon H, Little RF, Laubach C, LeBlanc M, Freidberg JW, Smith SM. SWOG 1918: A Phase II/III randomized study of R- miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geri Oncol. 2022;13(2):258-264.

Brem E, Thudium K, et al. Obatoclax possesses a dual Mechanism of action and potentiates the anti-tumor effects of rituximab or chemotherapy in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology. 2011;153:599-611.

American Society of Hematology (ASH)

American Society of Clinical Oncology (ASCO)

American Association of Cancer Research (AACR)

Alpha Omega Alpha

University of California Hematologic Malignancies Consortium

Medical Oncology Association of Southern California (MOASC)

Southwest Oncology Group (SWOG)

Internal Medicine Resident
Beth Israel Deaconess Medical Center/Harvard Medical School 2010—2013

Hematology/Oncology Fellow
Beth Israel Deaconess Medical Center/Harvard Medical School 2013—2016

Chao Family Comprehensive Cancer Center

Link to this profile
https://faculty.uci.edu/profile/?facultyId=6289

Last updated
04/01/2024